WHAT IS CLAIMED:

1. A pharmaceutical composition consisting of:

(a) an isolated population of cells comprising stimulated placental derived adherent cell, wherein said cell is adherent to tissue culture plastic, and wherein said cell is CD10+, $CD34^-$, $CD105^+$ and $CD200^+$, wherein said cell has been contacted with one or more pro-inflammatory cytokines *in vitro* such that said stimulated placental derived adherent cell secretes one or more trophic factors selected from the group consisting of: GM-CSF, G-CSF, IL-6, GRO, MCP-1, Follistatin, and IL-8 at a higher level than an isolated placental derived adherent cell that has not been contacted with said one or more pro-inflammatory cytokines; and

(b) at least one non-naturally occurring therapeutic agent,

wherein the one or more pro-inflammatory cytokines comprise IL-1 β.

2. Use of the pharmaceutical composition of Claim 1 in the manufacture of a medicament for treating an individual having a diabetic foot ulcer (DFU),

wherein the pharmaceutical composition is to be administered to the individual on day 1 and day 8 with a stimulated placental derived adherent cell concentration of (i) 3×10^6; (ii): 1×10^7; or (iii) 3×10^7 of said cells, and the pharmaceutical composition is to be administered to the individual by transplantation, implantation, intramuscular injection, infusion, or delivery via catheter.

3. Use of the pharmaceutical composition of Claim 1 in the manufacture of a medicament for treating an individual having a diabetic foot ulcer (DFU), wherein the pharmaceutical composition is to be intramuscularly administered to the individual on days 1, 29 and 57 with a stimulated placental derived adherent cell concentration of (i) 3×10^6; or 3×10^7 of said cells.

4. The use of claim 2 or claim 3, wherein said DFU is caused by and/or associated with peripheral arterial disease (PAD).